2021 Fiscal Year Final Research Report
Investigation of the anti-inflammatory mechanism of beta2 adrenergic receptor-IL-6 axis activation
Project/Area Number |
19K07118
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 47040:Pharmacology-related
|
Research Institution | Tokyo University of Agriculture and Technology |
Principal Investigator |
Eriko Suzuki 東京農工大学, (連合)農学研究科(研究院), 准教授 (00468513)
|
Co-Investigator(Kenkyū-buntansha) |
蓮見 惠司 東京農工大学, (連合)農学研究科(研究院), 教授 (20208474)
|
Project Period (FY) |
2019-04-01 – 2022-03-31
|
Keywords | 抗炎症作用 / アドレナリン受容体 / IL-6 / 脂肪組織 |
Outline of Final Research Achievements |
We have previously found that SMTP, a bioactive compound which shows excellenct anti-inflammatory effect in various animal models via the inhibition of soluble epoxide hydrolase (sEH). In this study, we have demonstrated that the anti-inflammatory effect was due to a gradual increase of plasma IL-6, a pleiotropic cytokine responsible for the regulation of inflammation. We also found that beta2 adrenergic receptor activation mainly in muscle and adipose tissue is involved as a responsible mechanism, and that enhancement of b2AR-IL-6 signal by N-phos inhibition is essential for the regulation of inflammation.
|
Free Research Field |
細胞生物学
|
Academic Significance and Societal Importance of the Research Achievements |
炎症が関与する疾患は多種多様であり、それゆえ炎症の制御は疾病の治療・予防や人々のQOLの向上に寄与する重要な命題である。本研究において報告した、アドレナリン受容体を介したIL-6発現の緩徐な上昇を介した炎症制御メカニズム、また可溶性エポキシドヒドロラーゼN末端ホスファターゼ阻害によるこのシグナルの増強は、炎症制御の新しい作用点を提唱するものであり、新規治療薬開発や炎症性疾患の発症・増悪化の機序の解明に貢献しうる、新しい発見である。
|